2.49
Cabaletta Bio Inc stock is traded at $2.49, with a volume of 5.30M.
It is up +7.33% in the last 24 hours and up +35.33% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.32
Open:
$2.43
24h Volume:
5.30M
Relative Volume:
2.23
Market Cap:
$227.75M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.50
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+2.05%
1M Performance:
+35.33%
6M Performance:
+102.44%
1Y Performance:
-40.86%
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CABA
Cabaletta Bio Inc
|
2.49 | 212.20M | 0 | -67.68M | -54.24M | -1.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-10-25 | Resumed | Jefferies | Buy |
Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-10-24 | Initiated | UBS | Buy |
Feb-05-24 | Initiated | Jefferies | Buy |
Nov-29-23 | Initiated | William Blair | Outperform |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-19-23 | Initiated | Stifel | Buy |
Sep-05-23 | Initiated | Citigroup | Buy |
Jul-18-23 | Initiated | Guggenheim | Buy |
Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Jun-30-21 | Initiated | Mizuho | Buy |
Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
Oct-13-20 | Initiated | H.C. Wainwright | Buy |
Nov-19-19 | Initiated | Cowen | Outperform |
Nov-19-19 | Initiated | Evercore ISI | Outperform |
Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Measuring Cabaletta Bio Inc.’s beta against major indicesTrade Signal Summary & Daily Profit Focused Stock Screening - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025July 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Can Cabaletta Bio Inc. hit a new high this monthJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsQuarterly Profit Summary & Long-Term Capital Growth Ideas - newser.com
Tools to monitor Cabaletta Bio Inc. recovery probabilityEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Cabaletta Bio Inc. stock trendline breakdown2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus
Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener
Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus
Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener
Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times
What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
What candlestick patterns are forming on Cabaletta Bio Inc.July 2025 Gainers & Precise Buy Zone Identification - newser.com
Published on: 2025-10-09 01:46:57 - newser.com
How to use Fibonacci retracement on Cabaletta Bio Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Myasthenia Gravis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma - Barchart.com
Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha
Using fundamentals and technicals on Cabaletta Bio Inc.July 2025 Recap & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Cabaletta Bio Inc. with AIPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Published on: 2025-10-01 06:55:18 - newser.com
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):